BioLife (BLFS) EV/EBITDA Multiple
BioLife Solutions, Inc. (BLFS) invests in advanced biomaterials and cloud IT solutions. Revenues are based on B2B supplies of cryochambers and solutions for medical centers. The company is currently scaling high-margin software while reducing its hardware segment. Analyzing the EV/EBITDA enterprise value multiple chart on GURU.Markets, we see market dynamics where the 286.33 indicator points to the company's resilience to financial shocks.
Analytical breakdowns for BioLife Solutions, Inc.
- current price and projected stock value:
- market capitalization details:
- issuer book value statistics:
- debt burden and liquidity indicators:
Debt to Equity BioLife Solutions, Inc.|BLFS - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity BioLife Solutions|BLFS - Company Cumulative Debt|Debt to Book Capitalization Ratio BioLife|BLFS - Company Long-Term Debt|Company Current Liabilities BioLife Solutions|Quick Liquidity Indicator biolifesolutions.com
- financial results and valuation multiples details:
BLFS - Profit After Payment of Taxes|Projected Future Earnings BioLife Solutions, Inc.|BLFS - Business Payback Period|Future Price to Earnings BioLife Solutions, Inc.|BLFS - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BioLife|BLFS - Operating profit before amortization|Earnings per share for the last twelve months BioLife Solutions|BLFS - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months biolifesolutions.com|BLFS - Earnings per share increase in current year|Earnings growth forecast for next year BioLife Solutions, Inc.
Initial company analysis:BLFS (BioLife Corp)
The development of the cell therapy sector provides BioLife Solutions, Inc. (BLFS) with a steady stream of revenue from the sale of consumables, rendering the business resilient. The ratio of enterprise value to EBITDA allows for an objective assessment of the business scale inclusive of debt; therefore, the EV/EBITDA trend for BioLife Solutions, Inc. (BLFS) helps investors filter out market noise and identify the asset's true fundamental value.
Who BioLife Solutions, Inc. competes with
EV/EBITDA Multiple TEM (tempus.com)|Total Company Value to Operating Income Before Depreciation Ratio Qiagen Corp (QGEN)|Ionis Pharmaceuticals - EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio RGEN|RNA: EV/EBITDA Multiple|Company Value to EBITDA CRISPR Therapeutics Inc (CRSP)|Enterprise Value to EBITDA Ratio WGS|RARE: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Beam Therapeutics Inc. (BEAM)|Total Company Value to Operating Income Before Depreciation Ratio sarepta.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Twist Bioscience, Inc. TWST|10x Genomics Inc (TXG) - Company Value to EBITDA|NTLA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|STOK: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|WVE (Wave Life Sciences) - Enterprise Value to EBITDA Ratio|mazetx.com (MAZE) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio SION|PRME (Prime Medicine Inc) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple TSHA|Total Company Value to Operating Income Before Depreciation Ratio uniQure Pharma|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MeiraGTx Holdings plc MGTX|regenxbio.com (RGNX) - Company Value to EBITDA|SLDB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OCGN (Ocugen Inc) - Enterprise Value to Operating Income Before Depreciation|Pacific Biosciences of California (PACB) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BNTC - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio DSGN|RCKT: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple FDMT|Total Company Value to Operating Income Before Depreciation Ratio lexeotx.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Korro Bio KRRO|EDIT: Enterprise Value to Operating Income Before Depreciation|Silence Therapeutics - EV/EBITDA Multiple|ProQR Therapeutics N.V. (PRQR) - Enterprise Value to EBITDA Ratio|CDXS (codexis.com) - Enterprise Value to EBITDA Ratio|SGMO - Total Company Value to Operating Income Before Depreciation Ratio|NAUT (Nautilus Biotechnology, Inc.) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MGX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Precision BioSciences (DTIL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GBIO (generationbio.com)|EV/EBITDA Multiple BOLD (Boundless Bio)|XCUR (Exicure Inc.) - Company Value to Operating Income Before Depreciation Ratio|IMNN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Phio Pharmaceuticals PHIO|MBIO: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation RNAZ|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bionano Genomics Inc.|Enterprise Value to Operating Income Before Depreciation APDN (Applied DNA Sciences Inc)|EV/EBITDA Multiple BLUE|EV/EBITDA Multiple immunoprecise.com (IPA)|EV/EBITDA Multiple OMGA (Omega Therapeutics)|singulargenomics.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Regulus Therapeutics Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Syros Pharmaceuticals Inc. SYRS|Codex DNA (TBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA TRACON Pharmaceuticals, Inc (TCON)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology
